8/12/2019 Rituparna Power Point Representation
1/25
RITUPARNA DAS
ROLL :99/05/PG-III
NO: 130035
3rd SEMESTER
Department of Chemistry
University of North Bengal
8/12/2019 Rituparna Power Point Representation
2/25
SOLID LIPID NANO PARTICLES:
Solid lipid nanoparticles (SLN) made from solid lipids are
attracting major attention as novel colloidal drug carrier for intravenous
applications as they have been proposed as an alternative particulate
carrier system. SLN are sub-micron colloidal carriers ranging from 50 to
1000 nm, which are composed of physiological lipid, dispersed in wateror in aqueous surfactant solution.
Fig.1:Structure of solid lipid nanoparticle
8/12/2019 Rituparna Power Point Representation
3/25
Fig.2:A diagrammatic representation on SLN overemulsions and liposomes
8/12/2019 Rituparna Power Point Representation
4/25
: Advantages of SLN :
Use of biodegradable physiological lipids which decreases the danger of acute and
chronic toxicity and avoidance of organic solvents in production methods .
Improved bioavailability of poorly water soluble molecules .
Site specific delivery of drugs, enhanced drug penetration into the skin via dermal
application .
Possibility of scaling up.
SLNs have better stability compared to liposomes .
8/12/2019 Rituparna Power Point Representation
5/25
Lyophilization possible
Much easier to manufacture than biopolymeric nanoparticles.
No special solvent required.
Raw materials essential the same as in emulsions.
Very high long-term stability.
Application versatility.
Can be subjected to commercial sterilization procedures.
8/12/2019 Rituparna Power Point Representation
6/25
: Disadvantages of SLN :
Poor drug loading capacity.
Drug expulsion after polymeric transition during storage .
Relatively high water content of the dispersions .
Particle growth.
Unpredictable gelation tendency.
8/12/2019 Rituparna Power Point Representation
7/25
Methods of Preparation:
1.High pressure homogenization
i. Hot homogenization
ii. Cold homogenization
2.Ultrasonication homogenization
3. Solvent evaporation method
4.Solvent emulsification-diffusion
method
5.Spray drying method
6.Supercritical Fluid technology
7.Microemulsion based method
8.Double emulsion method
9.Precipitation technique
10.Film-ultrasound dispersion
8/12/2019 Rituparna Power Point Representation
8/25
: Nanostructured lipid carriers (NLC) :
Nanostructured lipid carriers (NLC) are the second generation
SLN composed of solid lipid matrix which are incorporated with liquid lipids.
NLC with less organized crystalline structure and therefore provides better
loading capacity for drug accommodation. To overcome the stability and drug
expulsion problems of SLN, the NLC had emerged.
Fig.3:Electron microscopy picture of NLC
8/12/2019 Rituparna Power Point Representation
9/25
: Aims of solid lipid nanoparticles :
Possibility of controlled drug release.
Increased drug stability.
No bio-toxicity of the carrier.
: Materials used in SLN :
My system of SLN is Soya lecithin , Tripalmitine and Cetylpalmitate. The surfactant I used is Brij-35, a nonionic surfactant.
8/12/2019 Rituparna Power Point Representation
10/25
Fig4: Structural formula of
soyalecithine(C42H80NO8P)
Fig5: Structural formula of Cetyl
palmitate(C32H64O2)
Fig6:Structural formula of
tripalmitine(C51H98O6)
Fig7: Structural formula of Brij-35(C58H118O24)
8/12/2019 Rituparna Power Point Representation
11/25
: Reason for choosing this type of system:
There is Structural similarity between the components of mysystem. Brij-35 is easily biodegradable and non toxic as it is used as
my surfactant.
: Applications of SLN :
Solid lipid nanoparticles in Drug delivery:
Fig 13: Drug delivery By nanoparticles
8/12/2019 Rituparna Power Point Representation
12/25
Solid lipid nanoparticles in cancer chemotherapy:
Fig.14:A chemotherapy-f il led nanopart icle (lavender) i s coated with targeting molecules (blue-purple) that bind to cancer cell s. Once the
nanoparti cle is inside a cell , it releases the drugs (yell ow). [Ar t:
Nicolle Rager Full er]
SLN for Parenteral Application:
Cationic SLN has been demonstrated to bind genes directly via
electrostatic interactions, and have potential benefits in targeted gene
therapy in treatment of cancer.
8/12/2019 Rituparna Power Point Representation
13/25
Targeted delivery of solid lipid nanoparticles for the treatment of lung diseases:
Fig.15:Targeted deli very of solid li pid nanoparti cles for the treatment of l ung diseases
8/12/2019 Rituparna Power Point Representation
14/25
: Analytical characterization of SLN :
Measurement of particle size and zeta potential:
1.Dynamic light scattering (DLS):
DLS also known as PCS records the variation in the intensity of the
scattered light on the microsecond time scale.
Fig9:Intensity vs size diagram of Solid Lipid NanoParticles
8/12/2019 Rituparna Power Point Representation
15/25
2.Electron microscopy:
Fig 10:Elecronic microscopic image of Solid Lipid NanoParticles3.Atomic force microscopy (AFM):
Fig 11:AF M image of Solid lipid nanoparticles
8/12/2019 Rituparna Power Point Representation
16/25
: Plan of Work :The present work aims at the following:
To characterize the solid lipid nano particles.
8/12/2019 Rituparna Power Point Representation
17/25
: Experiment :
: Material : Lipid soylecithin, tripalmitine and cetyl palmitate
(SLC:TP) Wt% of CP SLC(mg) TP(mg) CP(mg) Total(mL)1:1 5% 7.2 7.6 0.5 201:1 10% 6.8 7.2 0.9 201:1 15% 6.4 6.8 1.4 201:1 20% 6.0 6.4 1.9 201:1 25% 5.6 6..0 2.4 201:1 30% 5.3 5.6 2.8 20
Table:1.Composition of System
8/12/2019 Rituparna Power Point Representation
18/25
: Result :1:1 SLC-TP and 5% CP 1:1 SLC-TP and 10% CP 1:1 SLC-TP and 15% CPTime/day Size/nm Time/day Size/nm Time/day Size/nm1 226.3 2 183.6 1 199.62 140.1 7 206.3 7 202.74 168.4 13 218.7 20 178.511 168.1 20 160.6 27 174.224 169 26 159 78 149.830 147.9 77 153.9 84 142.881 141.6 83 144.787 148.7
1:1 SLC-TP and 20% CP 1:1 SLC-TP and 25% CP 1:1 SLC-TP and 30% CPTime/day
Time/day
Time/day
Size/nm
Time/day
Size/nm
2 229.9 1 215.5 4 179.68 190.2 7 196.4 5 181.415 182.1 14 176.5 12 173.821 186.1 20 179.4 18 167.672 173.4 71 146.1 69 159.778 172.8 77 138.2 75 151.3
Table2: Variation in the hydrodynamic diameter of SLN at different time intervals.
8/12/2019 Rituparna Power Point Representation
19/25
0 20 40 60 80 100
140
160
180
200
220
240
260
size/nm
time/day
CP 5%
CP 10%
CP 15%CP 20%
CP 25%
CP 30%
Graph1:Variation in the hydrodynamic diameter of SLN at different time intervals.
8/12/2019 Rituparna Power Point Representation
20/25
Wt % of CP Zeta Potential5 -5.7210 -12.115 -4.8420 -13.525 -9.0830 -16.7
Table3: Variation in the Zeta Potential of SLN with varying concentration of Wt % of CP:
5 10 15 20 25 30
-18
-16
-14
-12
-10
-8
-6
-4
Zetapotential/mv
wt % of CP
zeta potential
Graph2:Variation in the Zeta Potential of SLN at different Wt% of CP
8/12/2019 Rituparna Power Point Representation
21/25
: Conclusion :
From the graph 1 the solution containing 20%
wt of CP is quite stable. It take 20 days to reach
equllibrating position . Others show much fluctuation .
There is a net decrease of Zeta potential value
with increasing concentration of CetylPalmitate(Graph:2)
. Results are further evidenced through above Figure
8/12/2019 Rituparna Power Point Representation
22/25
-:FUTURE PROSPECTIVE:-However, to draw final conclusion on this
aspect, further studies using varios
combination of lipids are warranted.This can be considered as the future
perspective.
8/12/2019 Rituparna Power Point Representation
23/25
: Acknowledgment:
I wish to express my sincere thanks and gratitude to myteacher Dr. A.K. Panda for his immensely valuable guidance
and suggestions to complete this work. My thanks and
appreciation also goes to all the faculty members of the
Department of Chemistry, University of North Bengal fortheir help and encouragement.
I am also thankful to the research fellows Gourab
Karmakar,Prasant Nahak, Manish Sapkota, Biplab , BanitaSinha, Moumita Chakraborty, Pritam Guha and my friends
for their constant support and encouragement in every
step.during this project work.
8/12/2019 Rituparna Power Point Representation
24/25
:References:
1. Coleman Anthony W., Jebors Said, et al. (2008). "para-Acylcalix[n]arenes: from molecular to
macroscopic assemblies." Chem. Commun.
2. DA SILVA ADRIANA L. , SANTOS RAQUEL S. , et al. (2012). "Nanoparticle-based therapy for
respiratory diseases." An. Acad. Bras. Cinc 85.
3. EKAMBARAM. P, S. A. A. HASAN, et al. (2012). "SOLID LIPID NANOPARTICLES: A REVIEW."
Sci. Revs. Chem. Commun 2(1): 80-102.
4. Gambhire Makarand Suresh , Bhalekar Mangesh Ramesh , et al. "Statistical optimization of dithranol-
loaded solid lipid nanoparticles using factorial design." Brazilian Journal of Pharmaceutical Sciences 47.
5. Garud Akanksha, Singh Deepti, et al. (2012). "Solid Lipid Nanoparticles (SLN): Method,
Characterization and Applications." International Current Pharmaceutical Journal 1(11): 384-393.
6. EH, Korkmaz E, et al. (2012). "Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid
carriers: evaluation of antioxidant potential for dermal applications." Int J Nanomedicine
7. Sahu MK, Soni GC, et al. (2012). "Nanostructured Lipid Carrier: The Second Generation of Solid Lipid
Nanoparticle." International Journal for Pharmaceutical Research Scholars (IJPRS) 1(3).
8. Singhal Girish B., Patel Rakesh P., et al. (2011). "SOLID LIPID NANO PARTICLES AND NANO
LIPID CARRIERS: AS NOVEL SOLID LIPID BASED DRUG CARRIER." International Reseach Journal
Of Pharmacy 2(2): 40-52.
9. Wissinga S.A., Kayserb O. , et al. (2003). "Solid lipid nanoparticles for parenteral drug delivery."
Advanced Drug Delivery Reviews: 1257-1272.
8/12/2019 Rituparna Power Point Representation
25/25
THANK YOU